Metastatic peritoneal carcinoma represents a complex challenge where cancer from another organ—most often the ovaries, colon, stomach, appendix, or pancreas—spreads to the peritoneum, the thin membrane that lines the abdominal cavity and protects internal organs. This condition, typically classified as stage IV disease, has historically carried a difficult prognosis, but evolving treatment approaches combining specialized surgery with innovative chemotherapy techniques are changing outcomes and offering new hope to patients facing this advanced cancer.

Understanding the Goals of Treatment for Peritoneal Spread

When cancer reaches the peritoneum, the primary focus shifts to managing symptoms, slowing disease progression, and improving quality of life for as long as possible. Treatment decisions depend heavily on how extensively the cancer has spread throughout the abdominal cavity, the type of original cancer involved, and the patient’s overall health and strength. The peritoneum is a membrane that covers the inner lining of the abdomen and the organs within it, and when cancer cells establish themselves there, they can cause serious complications like fluid buildup, bowel blockage, and progressive organ dysfunction.^[1]

Medical teams work with a combination of approaches that have been approved by medical societies and health authorities, alongside ongoing research into experimental therapies. Standard treatments aim to remove as much cancer as possible through surgery and destroy remaining cells with chemotherapy. Meanwhile, researchers continue exploring new molecules, techniques, and combinations in clinical trials around the world. Not every patient will be eligible for all treatments—decisions must be individualized based on the extent of cancer spread, measured through scoring systems like the Peritoneal Carcinomatosis Index (PCI), which maps tumor locations and sizes throughout the abdomen.^[2]

The reality is that peritoneal metastases usually appear when the original cancer has reached an advanced stage. In approximately 10% of cases, cancer travels to the peritoneum from organs outside the abdominal cavity, using the bloodstream or lymphatic system as pathways. More commonly, though, cancer spreads from nearby abdominal organs. This distinction matters because treatment strategies may differ depending on the cancer’s origin and behavior.^[2]

Standard Treatment Approaches

The cornerstone of treating peritoneal carcinomatosis when surgery is possible involves a two-part approach: cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This combination has significantly changed the treatment landscape over the past three decades, transforming what was once considered a universally fatal condition into one where some patients can achieve extended survival and, in select cases, even long-term disease control.^[17]

Cytoreductive surgery aims to remove all visible tumor deposits from the peritoneum and affected organs. Surgeons may need to remove portions of the peritoneum itself along with parts of organs that have tumor implants—this could include sections of the intestine, spleen, or other structures depending on where cancer has spread. The goal is to achieve what surgeons call “complete cytoreduction,” meaning no tumor nodules larger than 2.5 millimeters remain visible at the end of surgery. This extensive operation can take many hours and requires significant expertise.^[2]

Immediately following tumor removal, while the patient is still in the operating room, HIPEC is administered. This involves filling the abdominal cavity with heated chemotherapy solution—typically warmed to between 41 and 43 degrees Celsius (approximately 106 to 109 degrees Fahrenheit). The solution bathes all internal surfaces for 60 to 90 minutes while the surgical team gently manipulates the abdomen to ensure the heated medication reaches all areas. The heat itself helps destroy microscopic cancer cells that cannot be seen or removed surgically, and it also enhances the chemotherapy’s ability to penetrate tissue. After treatment, the solution is drained, and the surgical incision is closed.^[2]

The specific chemotherapy drugs used during HIPEC vary depending on the original cancer type. For colorectal and appendiceal cancers, medications like mitomycin C or oxaliplatin are commonly selected. For ovarian cancer, cisplatin or carboplatin might be used. The choice reflects decades of research into which agents work best against particular cancer types when delivered directly into the abdominal cavity at elevated temperatures.^[9]

Another technique called early postoperative intraperitoneal chemotherapy (EPIC) involves administering chemotherapy through catheters left in the abdomen for several days after surgery. This approach delivers medication at normal body temperature but extends the treatment period. Some centers use EPIC in addition to or instead of HIPEC, depending on the specific circumstances and institutional protocols.^[5]

Recovery from cytoreductive surgery with HIPEC is substantial. Patients typically remain hospitalized for one to three weeks, depending on the extent of surgery and any complications. Common side effects include pain at the surgical site, temporary changes in bowel function as the intestines recover, fatigue, and sometimes low blood counts as the bone marrow responds to chemotherapy exposure. Serious complications can include infections, bleeding, bowel leaks, or kidney problems from the chemotherapy. The mortality rate from the procedure itself ranges from 2% to 5% at experienced centers, emphasizing the importance of seeking care from specialized teams who perform these operations frequently.^[9]

For patients who cannot undergo surgery, or when cancer returns after initial treatment, systemic chemotherapy administered through the bloodstream remains an option. Standard regimens used for the original cancer type—such as FOLFOX or FOLFIRI for colorectal cancer—may help slow disease progression and manage symptoms. These medications circulate throughout the body and can address cancer spread beyond the peritoneum. However, peritoneal metastases often respond less completely to systemic chemotherapy alone compared to cancer in other locations, because the dense fibrous tissue and poor blood supply in the peritoneum limit drug penetration.^[5]

When fluid accumulation in the abdomen, known as ascites, causes significant discomfort, shortness of breath, or abdominal pressure, a procedure called paracentesis can provide relief. Using a needle inserted through the abdominal wall, doctors drain excess fluid—sometimes several liters at a time. While this doesn’t treat the underlying cancer, it temporarily improves symptoms and quality of life. Some patients require repeated paracentesis procedures as fluid reaccumulates.^[1]

Innovative Treatments in Clinical Trials

Researchers worldwide are investigating new ways to treat peritoneal metastases through clinical trials, which test experimental therapies before they become widely available. These studies typically progress through three phases: Phase I trials focus primarily on safety and determining appropriate doses; Phase II trials assess whether the treatment shows signs of effectiveness against the cancer; and Phase III trials compare the new approach against current standard treatments to determine if it offers better outcomes.^[9]

One promising area involves a newer technique called pressurized intraperitoneal aerosol chemotherapy (PIPAC). Unlike HIPEC, which requires major surgery, PIPAC can be performed through small laparoscopic incisions. Chemotherapy is converted into a fine mist or aerosol and delivered under pressure into the sealed abdominal cavity. The pressure helps the medication penetrate deeper into tissue, while the aerosol form ensures even distribution across all peritoneal surfaces. PIPAC can be repeated every 4 to 6 weeks, making it suitable for patients who cannot tolerate extensive surgery or have disease that keeps returning.^[11]

Early clinical experience with PIPAC has shown that it can reduce tumor deposits visible during subsequent procedures, and some patients report improvement in symptoms like ascites production. The side effects are generally milder than those from HIPEC, though patients may experience temporary abdominal pain, nausea, or changes in bowel function for a few days after each treatment. Researchers are still determining which patients benefit most from PIPAC and how it compares to or might complement other treatments. Studies are ongoing in Europe and increasingly in other regions.^[11]

Targeted therapy represents another frontier in clinical trials. Scientists are exploring molecules that interfere with specific pathways cancer cells use to grow and spread. For instance, bevacizumab, a medication that blocks blood vessel formation (a process called angiogenesis), has shown promise when combined with chemotherapy for some patients with peritoneal metastases from colorectal cancer. By preventing tumors from developing the blood supply they need to grow, these drugs may slow disease progression. Clinical trials are testing various combinations and schedules to optimize effectiveness while minimizing side effects like high blood pressure, bleeding problems, or impaired wound healing.^[9]

Immunotherapy approaches are also under investigation. These treatments harness the body’s immune system to recognize and attack cancer cells. While immunotherapy has shown remarkable success in certain cancers like melanoma and lung cancer, its effectiveness in peritoneal metastases has been more limited so far. However, researchers are testing whether combining immune checkpoint inhibitors—medications that release the “brakes” on immune cells—with chemotherapy or other treatments might improve outcomes. Some trials focus specifically on patients whose tumors have particular genetic features that make them more likely to respond to immunotherapy.^[9]

Several trials are examining ways to improve the delivery and effectiveness of intraperitoneal chemotherapy. One approach involves using nanoparticles—microscopic particles that can carry chemotherapy drugs directly to cancer cells while limiting exposure to healthy tissue. These particles might be engineered to release their payload only when they encounter specific conditions found in tumors, potentially reducing side effects while increasing cancer-killing power. This technology remains experimental but represents an exciting direction for future treatment development.^[9]

Another research avenue explores whether preventive treatment might help patients at high risk of developing peritoneal metastases. For example, some trials are testing whether administering intraperitoneal chemotherapy at the time of initial cancer surgery—before visible peritoneal spread occurs—can prevent cancer cells from establishing themselves in the peritoneum. This strategy, sometimes called “prophylactic HIPEC,” is being studied in colorectal cancer patients whose tumors have features suggesting high risk for peritoneal recurrence, such as perforation or deep invasion through the bowel wall.^[17]

Geographic access to clinical trials varies considerably. Major cancer centers in the United States, Europe, and increasingly in Asia tend to offer the widest range of trial options. However, patients should inquire with their local oncology team about trials available in their region or whether participation in distant trials might be feasible. Many institutions maintain registries of available trials, and national organizations provide searchable databases to help patients and doctors identify potentially suitable studies.^[9]

Most Common Treatment Methods

• Surgical Treatment
  • Cytoreductive surgery removes all visible tumor deposits from the peritoneum and affected organs, sometimes requiring removal of portions of the peritoneum itself and parts of affected organs
  • Staging laparoscopy uses a small camera to inspect the abdominal cavity and determine the extent of disease before major surgery
  • The goal is complete cytoreduction, leaving no tumor nodules larger than 2.5 millimeters visible
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
  • Heated chemotherapy solution (41-43°C) is circulated through the abdominal cavity for 60-90 minutes during surgery
  • Heat helps destroy microscopic cancer cells and enhances chemotherapy penetration into tissue
  • Common drugs include mitomycin C or oxaliplatin for colorectal/appendiceal cancers, and cisplatin or carboplatin for ovarian cancer
• Systemic Chemotherapy
  • Medications delivered through the bloodstream for patients who cannot undergo surgery or when disease returns
  • Standard regimens like FOLFOX or FOLFIRI used for colorectal cancer
  • Limited effectiveness due to poor drug penetration into peritoneal tissue
• Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
  • Chemotherapy delivered as a pressurized aerosol through small laparoscopic incisions
  • Can be repeated every 4-6 weeks
  • Suitable for patients unable to tolerate extensive surgery
  • Currently being studied in clinical trials, particularly in Europe
• Symptom Management Procedures
  • Paracentesis drains accumulated abdominal fluid (ascites) to relieve discomfort and breathing difficulties
  • May need to be repeated as fluid reaccumulates
  • Provides temporary symptom relief without treating underlying cancer
• Targeted Therapy
  • Medications like bevacizumab that block blood vessel formation to tumors
  • Being tested in clinical trials in combination with chemotherapy
  • Focus on interfering with specific pathways cancer cells use to grow
• Immunotherapy
  • Immune checkpoint inhibitors that help the body’s immune system recognize and attack cancer cells
  • Currently being evaluated in clinical trials
  • Some trials focus on patients with specific genetic features